FAKTOR OPTIONSSCHEIN - VERTEX PHARMACEUTICALS | Market Closed - BOERSE MUENCHEN 15:46:09 2024-06-21 EDT | ||
| 12.68 EUR | -1.32% |
|
| Current month | +14.96% | ||
| 1 month | +35.18% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-06-21 | 12.68 | -1.32% |
| 24-06-20 | 12.85 | +5.67% |
| 24-06-19 | 12.16 | -0.90% |
| 24-06-18 | 12.27 | -8.23% |
| 24-06-17 | 13.37 | -9.29% |
Real-time BOERSE MUENCHEN
Last update June 21, 2024 at 03:46 pm
More quotesStatic data
| Product type | Produits Exotiques |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
UniCredit
|
| WKN | HD33L5 |
| ISIN | DE000HD33L55 |
| Date issued | 2024-02-27 |
| Strike | 392.9 $ |
| Maturity | Unlimited |
| Parity | 6.11 : 1 |
| Emission price | 10.57 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 15.54 € |
|---|---|
| Lowest since issue | 4.72 € |
| Spread | 0.04 € |
| Spread % | 0.32% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
468.7
USD
Average target price
463.4
USD
Spread / Average Target
-1.13%
- Stock Market
- Certificates
- Certificat
